RAAS Inhibitors Clinical Trialists Collaboration (RiCTC)

 

The RAAS Inhibitors Clinical Trialists Collaboration includes trials randomising participants with COVID-19 to RAAS inhibition or placebo and standard care. The aim is to perform individual participant data (IPD) level analyses to answer questions that are not addressed by any single trial. This will provide a greater number of trial participants and study power to estimate effect, perform subgroup analyses and to ensure the maximum knowledge is gained from the effort put into these trials.

Individual participant data (IPD) meta-analysis serves a different and unique function and mitigates limitations from aggregate meta-analyses.  An IPD analysis can be defined as the calculation of a summary across primary empirical studies using the raw data collected. The IPD analyses will be able to inform evidence-based practice surrounding RAAS inhibition in COVID-19 patients.

Individual patient data from each contributing trial provided to the RiCTC Collaboration will only be used for the purpose of IPD analyses. The RiCTC Collaborators will have an opportunity to contribute to analyses of the data, interpretation of the results and drafting of the reports before publication.

 

Aim:

RiCTC aims to collaborate with trials randomising patients with COVID-19 to RAAS inhibition to perform individual participant data (IPD) level analyses.

Supported By:

N/A

Eligibility:

N/A

Registration ID:

N/A

Participation:

International

Australian Lead Group:

NHMRC CTC

Status:

In Development

Activation Date:

2021

Chair:

Professor Meg Jardine

Contact:

Arlen Wilcox | Clinical Trial Program Manager

arlen.wilcox@ctc.usyd.edu.au

Publications:

Nil